For drug registration in Taiwan, clinical trials must demonstrate the drug’s safety, efficacy, and quality. These typically include Phase I trials for safety, Phase II for efficacy, and Phase III for large-scale testing. Bridging studies may also be required to confirm the relevance of foreign clinical data for the Taiwanese population.
